Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381965 | 0.89 | ALOX5 (0.45) | GRM5MAPTALOX5 | |
| SCHEMBL13381964 | 0.88 | KMT2A (0.45) | MEN1KMT2AMAPTP2RX3 | |
| SCHEMBL13382011 | 0.86 | MAOB (0.35) | MEN1KMT2A | |
| SCHEMBL13382001 | 0.85 | PTPRC (0.42) | MEN1KMT2AMAPTPTGDR2 | |
| SCHEMBL13382025 | 0.85 | FGFR1 (0.35) | MEN1KMT2A | |
| SCHEMBL13382094 | 0.83 | ALOX5 (0.39) | GRM5ALOX5 | |
| SCHEMBL13381879 | 0.83 | ALDH1A1 (0.42) | MEN1KMT2AMAPT | |
| SCHEMBL13382008 | 0.83 | MAOB (0.42) | MEN1KMT2AALOX5 | |
| SCHEMBL13381974 | 0.82 | RXRA (0.37) | MEN1KMT2AMAPTALOX5 | |
| SCHEMBL13381979 | 0.82 | ALDH1A1 (0.38) | MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | MEN1 4525/4885KMT2A 4087/4885GRM5 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.